2449 related articles for article (PubMed ID: 19998746)
1. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
2. Expanded access to investigational drugs for treatment use. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
[TBL] [Abstract][Full Text] [Related]
3. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
4. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
5. Individual patient treatment use of unapproved drugs: a new option for the seriously ill.
Simon LS; Green A
J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):19-22. PubMed ID: 20345195
[TBL] [Abstract][Full Text] [Related]
6. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
7. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Ochs A
Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
[No Abstract] [Full Text] [Related]
8. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
Food and Drug Administration. HHS
Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
[TBL] [Abstract][Full Text] [Related]
9. Access before approval--a right to take experimental drugs?
Okie S
N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
[No Abstract] [Full Text] [Related]
10. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
[TBL] [Abstract][Full Text] [Related]
11. The role of the FDA in the effort against AIDS.
Young FE
Public Health Rep; 1988; 103(3):242-5. PubMed ID: 3131814
[TBL] [Abstract][Full Text] [Related]
12. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
Lovell MC
Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202
[No Abstract] [Full Text] [Related]
13. Investigational new drug applications; clinical holds--FDA. Direct final rule.
Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
[TBL] [Abstract][Full Text] [Related]
14. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
Shulman SR; Brown JS
Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
[No Abstract] [Full Text] [Related]
15. FDA's compassion for desperate drug companies.
Annas GJ
Hastings Cent Rep; 1990; 20(1):35-7. PubMed ID: 2179165
[TBL] [Abstract][Full Text] [Related]
16. No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
Kelly JJ; David M
Food Drug Law J; 2009; 64(1):115-48. PubMed ID: 19998743
[TBL] [Abstract][Full Text] [Related]
17. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move.
Moss RW
New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956
[No Abstract] [Full Text] [Related]
18. The proper focus for FDA regulations: why the fundamental right to self-preservation should allow terminally ill patients with no treatment options to attempt to save their lives.
Puckett A
SMU Law Rev; 2007; 60(2):635-65. PubMed ID: 17849632
[No Abstract] [Full Text] [Related]
19. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
20. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
